In some aspects, the present disclosure pertains to systems for forming hydrogels that comprise (a) a first composition that comprises a polyiodinated polyamino compound that comprises a polyamino moiety linked to a polyiodinated aromatic moiety by an amide group or ester group and (b) a second composition that comprises a reactive multi-arm polymer that comprises a plurality of hydrophilic polymer arms having reactive end groups that are reactive with amino groups of the polyiodinated polyamino compound. Other aspects of the present disclosure pertain to medical hydrogels and methods of making medical hydrogels that are based on such compositions. Further aspects of the present disclosure pertain to methods of making polyiodinated polyamino compounds.

In some aspects, the present disclosure pertains to systems for forming hydrogels that comprise (a) a first composition that comprises a polyiodinated polyamino compound that comprises a polyamino moiety linked to a polyiodinated aromatic moiety by an amide group or ester group and (b) a second composition that comprises a reactive multi-arm polymer that comprises a plurality of hydrophilic polymer arms having reactive end groups that are reactive with amino groups of the polyiodinated polyamino compound. Other aspects of the present disclosure pertain to medical hydrogels and methods of making medical hydrogels that are based on such compositions. Further aspects of the present disclosure pertain to methods of making polyiodinated polyamino compounds.

Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

##STR00001##

Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

##STR00001##

Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity.

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity.

This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R.sup.1 is —CH.sub.2CH═C(CH.sub.3).sub.2, R.sup.2 is methyl, R.sup.3 is CsHn, R.sup.4 is —C(O)N(R.sup.4a)(R.sup.4b), R.sup.5 is H, R.sup.6 is OH, and R.sup.7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.

This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R.sup.1 is —CH.sub.2CH═C(CH.sub.3).sub.2, R.sup.2 is methyl, R.sup.3 is CsHn, R.sup.4 is —C(O)N(R.sup.4a)(R.sup.4b), R.sup.5 is H, R.sup.6 is OH, and R.sup.7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.

An object of the present invention is to provide a composition capable of forming a film having a high refractive index and excellent exterior characteristics. Another object of the present invention is to provide a film, a lens, and a solid-state imaging element in which the composition is used. Still another object of the present invention is to provide novel compounds. The composition according to an embodiment of the present invention contains a compound represented by General Formula (I), a solvent, and a resin, in which a solubility of the compound represented by General Formula (I) in the solvent is less than 0.5% by mass at 25° C., and a maximum absorption wavelength of the compound represented by General Formula (I) at a wavelength range of 300 to 800 nm is equal to or shorter than 450 nm.
AB-C).sub.n  (I)